Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive Giovanni Caforio as its ...

Suggested remit: To appraise the clinical and cost effectiveness of zanidatamab within its marketing authorisation for treating HER2-positive advanced biliary tract cancer after 1 or more systemic ...